These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Risks of testosterone-replacement therapy and recommendations for monitoring. Rhoden EL; Morgentaler A N Engl J Med; 2004 Jan; 350(5):482-92. PubMed ID: 14749457 [No Abstract] [Full Text] [Related]
5. [Testosterone replacement therapy for hypogonadism in men with prostate cancer]. Jensen CF; Fode M; Østergren P; Sønksen J Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152 [TBL] [Abstract][Full Text] [Related]
6. A new testosterone gel (fortesta) for hypogonadism. Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933 [TBL] [Abstract][Full Text] [Related]
7. Invasive breast cancer after initiation of testosterone replacement therapy in a man--a warning to endocrinologists. Thomas SR; Evans PJ; Holland PA; Biswas M Endocr Pract; 2008 Mar; 14(2):201-3. PubMed ID: 18308658 [TBL] [Abstract][Full Text] [Related]
8. A Comparison of Secondary Polycythemia in Hypogonadal Men Treated with Clomiphene Citrate versus Testosterone Replacement: A Multi-Institutional Study. Wheeler KM; Smith RP; Kumar RA; Setia S; Costabile RA; Kavoussi PK J Urol; 2017 Apr; 197(4):1127-1131. PubMed ID: 27984109 [TBL] [Abstract][Full Text] [Related]
9. Testosterone replacement therapy and cardiovascular events. Çatakoğlu AB; Kendirci M Turk Kardiyol Dern Ars; 2017 Oct; 45(7):664-672. PubMed ID: 28990951 [TBL] [Abstract][Full Text] [Related]
10. Testosterone administration in older men. Matsumoto AM Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401 [TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism. Sonmez A; Haymana C; Bolu E; Aydogdu A; Tapan S; Serdar M; Altun B; Barcin C; Taslipinar A; Meric C; Uckaya G; Kutlu M Eur J Endocrinol; 2011 May; 164(5):759-64. PubMed ID: 21325471 [TBL] [Abstract][Full Text] [Related]
12. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism. Santella C; Renoux C; Yin H; Yu OHY; Azoulay L Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457 [TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement therapy and prostate cancer: a word of caution. Brand TC; Canby-Hagino E; Thompson IM Curr Urol Rep; 2007 May; 8(3):185-9. PubMed ID: 17459266 [TBL] [Abstract][Full Text] [Related]
14. Reversal of polycythaemia induced by intramuscular androgen replacement using transdermal testosterone therapy. Siddique H; Smith JC; Corrall RJ Clin Endocrinol (Oxf); 2004 Jan; 60(1):143-5. PubMed ID: 14678301 [No Abstract] [Full Text] [Related]
15. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study. Li H; Mitchell L; Zhang X; Heiselman D; Motsko S J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802 [TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy: who to evaluate, what to use, how to follow, and who is at risk? Afiadata A; Ellsworth P Hosp Pract (1995); 2014 Dec; 42(5):69-82. PubMed ID: 25485919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]